SCHEMBL2485490

SCHEMBL2485490

CC(C)(C)OC(=O)N1CCC[C@H]1C(=O)Nc1ccc(Nc2cc(NCc3cc(F)cc(F)c3)c(C(N)=O)cn2)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.49
JAK2 O60674 4/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
JAK3 P52333 7/20 0.46
LMNA P02545 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
IRAK4 Q9NWZ3 2/20 0.44
JAK1 P23458 1/20 0.44
TYK2 P29597 1/20 0.44
HDAC8 Q9BY41 1/20 0.43
SIRT2 Q8IXJ6 2/20 0.43
USP30 Q70CQ3 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
AURKA O14965 1/20 0.41
ALDH1A1 P00352 1/20 0.41
STAT6 P42226 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2480978 0.91 JAK3 (0.56) NPC1JAK2MEN1KMT2AJAK3
SCHEMBL2480980 0.91 JAK3 (0.56) NPC1JAK2MEN1KMT2AJAK3
SCHEMBL2478606 0.87 PTPN2 (0.49) NPC1JAK2JAK3IRAK4JAK1
SCHEMBL25219392 0.81 F10 (0.45) JAK2JAK3IRAK4JAK1TYK2
SCHEMBL2485627 0.79 JAK3 (0.53) JAK2JAK3IRAK4JAK1TYK2
SCHEMBL2483165 0.78 JAK3 (0.54) JAK2JAK3IRAK4JAK1TYK2
SCHEMBL2483610 0.78 JAK3 (0.58) NPC1JAK2JAK3LMNAIRAK4
Hydrochloric Acid SCHEMBL2484490 0.78 JAK3 (0.52) JAK2JAK3IRAK4JAK1TYK2
SCHEMBL2483002 0.77 JAK3 (0.51) JAK2JAK3IRAK4JAK1TYK2
SCHEMBL2482999 0.77 JAK3 (0.51) JAK2JAK3IRAK4JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
CN-102227409-A Pyridine-3-carboxyamide derivative KOWA CO 2011-10-26 CN disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA NPC1 4679/4885JAK2 4/4885MEN1 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.